<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006519</article-id><article-id pub-id-type="pmc">PMC11859518</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics17020152</article-id><article-id pub-id-type="publisher-id">pharmaceutics-17-00152</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Novel Solid Forms of Cardarine/GW501516 and Their Characterization by X-Ray Diffraction, Thermal, Computational, FTIR, and UV Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1920-9272</contrib-id><name><surname>Turza</surname><given-names>Alexandru</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-pharmaceutics-17-00152" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-1239-5172</contrib-id><name><surname>Bosca</surname><given-names>Maria</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00152" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4460-9654</contrib-id><name><surname>Muresan-Pop</surname><given-names>Marieta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af3-pharmaceutics-17-00152" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Mare</surname><given-names>Liviu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00152" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Borodi</surname><given-names>Gheorghe</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af1-pharmaceutics-17-00152" ref-type="aff">1</xref><xref rid="c1-pharmaceutics-17-00152" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0062-2427</contrib-id><name><surname>Popescu</surname><given-names>Violeta</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><xref rid="af2-pharmaceutics-17-00152" ref-type="aff">2</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Zhang</surname><given-names>Li</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>Yang</surname><given-names>Dezhi</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceutics-17-00152"><label>1</label>National Institute For R&#x00026;D of Isotopic and Molecular Technologies, 67-103 Donat, 400293 Cluj-Napoca, Romania; <email>alexandru.turza@itim-cj.ro</email></aff><aff id="af2-pharmaceutics-17-00152"><label>2</label>Department of Physics and Chemistry, Technical University of Cluj-Napoca, 400114 Cluj-Napoca, Romania; <email>maria.bosca@phys.utcluj.ro</email> (M.B.); <email>liviu.mare@campus.utcluj.ro</email> (L.M.); <email>violeta.popescu@chem.utcluj.ro</email> (V.P.)</aff><aff id="af3-pharmaceutics-17-00152"><label>3</label>Institute of Interdisciplinary Research in Bio-Nano-Sciences, Babes Bolyai University, 42 Treboniu Laurian, 400271 Cluj-Napoca, Romania; <email>marieta.muresan@ubbcluj.ro</email></aff><author-notes><corresp id="c1-pharmaceutics-17-00152"><label>*</label>Correspondence: <email>borodi@itim-cj.ro</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><elocation-id>152</elocation-id><history><date date-type="received"><day>04</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>17</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>21</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Cardarine (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>), better known by the popular name of GW501516, is a peroxisome proliferator-activated receptor delta (PPR-&#x003b4;) agonist that presents potential use in the approach of cardiovascular diseases and metabolic disorders, dyslipidemia, and insulin resistance. The capability of cardarine to exhibit new solid forms by recrystallization from a broad class of solvents was explored. A total of four new solid forms were obtained: a new polymorph of cardarine (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>), the cardarine: 4,4&#x02032;-bipyridine cocrystal (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>&#x000b7;0.5C<sub>10</sub>H<sub>8</sub>N<sub>2</sub>), the cardarine methanol solvate (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>&#x000b7;CH<sub>3</sub>OH), and the cardarine dimethylformamide solvate (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>&#x000b7;C<sub>3</sub>H<sub>7</sub>NO). Moreover, two derivatives of cardarine were obtained, in the form of the mono-oxidized cardarine structure (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>4</sub>S<sub>2</sub>) and the dioxidized cardarine structure (C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>5</sub>S<sub>2</sub>). The formation process was proven by the determination of their crystal structures using single crystal X-ray diffraction and followed by their lattice energies evaluation. Further investigations have been conducted by powder X-ray diffraction, DTA/TGA thermal analysis, and FTIR spectroscopy. The stability and solubility were analyzed as well.</p></abstract><kwd-group><kwd>GW501516</kwd><kwd>cardarine</kwd><kwd>polymorphism</kwd><kwd>crystal structure</kwd><kwd>cocrystal</kwd><kwd>solubility</kwd></kwd-group><funding-group><award-group><funding-source>MCID</funding-source><award-id>PN 23 24 01 01</award-id></award-group><funding-statement>The authors acknowledge the financial support from the MCID through the &#x0201c;Nucleu&#x0201d; Programe within the National Plan for Research, Development and Innovation 2022&#x02013;2027, project PN 23 24 01 01.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceutics-17-00152"><title>1. Introduction</title><p>Cardarine, also known by the name of GW501516 (2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid), is a peroxisome proliferator-activated receptor delta (PPAR-&#x003b4;) agonist [<xref rid="B1-pharmaceutics-17-00152" ref-type="bibr">1</xref>] developed in the 1990s as a compound with potential use in cardiovascular and metabolic disorder treatment. Previous studies have shown that cardarine is efficient and has ameliorated some obesity-related parameters such as oxidative stress dyslipidemia and insulin resistance, which are related to metabolic disorders. The PPAR-&#x003b4; agents developed, including cardarine, are increasing the body&#x02019;s capacity to use fat as a primary source of fuel as an alternative to glucose [<xref rid="B2-pharmaceutics-17-00152" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-17-00152" ref-type="bibr">3</xref>]. The boost in fatty acid metabolism is gained based on the PPAR-&#x003b4; receptor activation by the upregulation of fatty acid uptake and oxidation [<xref rid="B4-pharmaceutics-17-00152" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-17-00152" ref-type="bibr">5</xref>]. Recent studies demonstrated that cardarine is efficient in the treatment of insulin resistance [<xref rid="B6-pharmaceutics-17-00152" ref-type="bibr">6</xref>] and subepithelial fibrosis during asthma as well [<xref rid="B7-pharmaceutics-17-00152" ref-type="bibr">7</xref>]. Due to the fact that it boosts the body&#x02019;s cardiovascular output, it gained rapid popularity among athletes and recreational users as a performance-enhancement drug [<xref rid="B8-pharmaceutics-17-00152" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-17-00152" ref-type="bibr">9</xref>]; nevertheless, its usage is prohibited by the World Anti-Doping Agency [<xref rid="B10-pharmaceutics-17-00152" ref-type="bibr">10</xref>].</p><p>The actual paper aims toward the capabilities of cardarine to be grown as new solid forms, which include cocrystals, salts, polymorphs, and solvates; even though the literature provides an extensive study of cardarine polymorphism [<xref rid="B11-pharmaceutics-17-00152" ref-type="bibr">11</xref>], the CSD database so far reports only five polymorphs of cardarine [<xref rid="B12-pharmaceutics-17-00152" ref-type="bibr">12</xref>]. The polymorphism of active pharmaceutical ingredients represents their ability to be packed within the crystal structure in various patterns [<xref rid="B13-pharmaceutics-17-00152" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-17-00152" ref-type="bibr">14</xref>,<xref rid="B15-pharmaceutics-17-00152" ref-type="bibr">15</xref>].</p><p>The formation of solid crystalline forms and multi-component molecular structures that contain at least two constituents are driven by noncovalent contacts such as hydrogen bonds, &#x003c0;&#x000b7;&#x000b7;&#x000b7;&#x003c0; stacking, and other van der Waals interactions [<xref rid="B16-pharmaceutics-17-00152" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-17-00152" ref-type="bibr">17</xref>]. Among the advantages and benefits of the solid forms, the following characteristics are worth mentioning: greater solubility, bioavailability, dissolution rate, melting point, and stability [<xref rid="B18-pharmaceutics-17-00152" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceutics-17-00152" ref-type="bibr">19</xref>,<xref rid="B20-pharmaceutics-17-00152" ref-type="bibr">20</xref>]. The fact that the structural makeup of cardarine, with the carboxyl COOH and the thiazol ring, makes it a suitable candidate for the formation of new crystalline forms via the interactions in a solid by hydrogen bonding must be taken into consideration (<xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>).</p><p>The recrystallization of cardarine in various solvents was achieved, generating four new solid crystalline forms, which consist of a new polymorph, one 4,4&#x02032;-bipyridine cocrystal (found in a 2:1 stoichiometric ratio), one methanol solvate, one dimethylformamide solvate, and two new cardarine derivatives, respectively. Their crystal structures were elucidated by single-crystal X-ray diffraction and the supramolecular features were explored by computational methods. Other methods to analyze the materials were DTA/TGA thermal analysis and FTIR spectroscopy. From a pharmaceutical point of view, the solubility of the polymorph, the cocrystal, the methanol, and dimethylformamide solvates were assessed. The stability of the polymorph and the 4,4&#x02032;-bipyridine cocrystal was evaluated under specific temperature and relative humidity conditions.</p></sec><sec id="sec2-pharmaceutics-17-00152"><title>2. Materials and Methods</title><sec id="sec2dot1-pharmaceutics-17-00152"><title>2.1. Recrystallization and Crystal Growth Experiments</title><p>The crystalline powder of cardarine was received from Wuhan Shu Mai Technology Co. (Wuhan, China) and solvents were received from Merck and Sigma-Aldrich (Taufkirchen, Germany).</p><p>The new solid forms and their suitable single crystals were prepared by slow evaporation from a wide class of solvents and mixtures. The solutions were kept in the refrigerator at a temperature of 4 &#x000b0;C and evaporated slowly during a period of up to two months. The four prepared crystalline forms and two derivatives are listed below and illustrated in <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>a&#x02013;f, as follows:<list list-type="simple"><list-item><label>(i)</label><p>Cardarine polymorph (GW-6, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>a) was obtained from a solution of methanol;</p></list-item><list-item><label>(ii)</label><p>Cardarine 4,4&#x02032;-bipyridine cocrystal (GW-Bipy, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>b) was obtained from multiple solutions such as acetonitrile, ethanol, and methanol;</p></list-item><list-item><label>(iii)</label><p>Cardarine methanol solvate (GW-MeOH, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>c) was prepared in a solution of methanol and water in a 1:1 volumetric ratio;</p></list-item><list-item><label>(iv)</label><p>Cardarine dimethylformamide solvate (GW-DMF, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>d) was obtained from a solution of dimethylformamide;</p></list-item><list-item><label>(v)</label><p>Cardarine, in the mono-oxidized form (GW-SO, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>e), was obtained from a solution of dimethyl sulfoxide but was not further reproduced;</p></list-item><list-item><label>(vi)</label><p>Cardarine, in the dioxidized form (GW-SO<sub>2</sub>, <xref rid="pharmaceutics-17-00152-sch001" ref-type="fig">Scheme 1</xref>f), was obtained from a mixture with nitromethane and was not further reproduced anymore.</p></list-item></list></p></sec><sec id="sec2dot2-pharmaceutics-17-00152"><title>2.2. Single-Crystal X-Ray Diffraction and Refinement</title><p>The single crystals were attached on a fine nylon loop coated by inert oil and mounted on the goniometer of a SuperNova diffractometer equipped with dual X-ray micro-sources (Mo and Cu), which operates at 50 kV and 0.8 mA and Eos CCD detector. The collection of experimental data and their correction process for Lorentz, polarization, and adsorption effects were accomplished in the CrysAlis PRO program [<xref rid="B21-pharmaceutics-17-00152" ref-type="bibr">21</xref>].</p><p>The crystal structures of GW-6 and GW-Bipy were solved by Direct Methods with the SHELXS solution program [<xref rid="B22-pharmaceutics-17-00152" ref-type="bibr">22</xref>], while GW-MeOH, GW-DMF, GW-SO, and GW-SO<sub>2</sub> were solved using Intrinsic Phasing with SHELXT [<xref rid="B23-pharmaceutics-17-00152" ref-type="bibr">23</xref>]. The structures were refined using Least Squares minimization by the SHELXL [<xref rid="B24-pharmaceutics-17-00152" ref-type="bibr">24</xref>] refinement package. All programs are implemented in the Olex2 package [<xref rid="B25-pharmaceutics-17-00152" ref-type="bibr">25</xref>].</p><p>Hydrogen atoms bounded to carbons were located, treated, and refined as riding, considering the isotropic displacement parameter U<sub>iso</sub>(H) = 1.2U<sub>eq</sub>(C) for ternary CH groups [C-H = 0.93 &#x000c5;], secondary CH<sub>2</sub> groups [C-H = 0.97 &#x000c5;], and 1.5U<sub>eq</sub>(C) considered for all methyl CH<sub>3</sub> groups [C-H = 0.96 &#x000c5;]. Hydrogen atoms bound to oxygen atoms were located by Fourier maps and by a riding procedure and refined with bond length distances of O-H = 0.82 &#x000c5;.</p></sec><sec id="sec2dot3-pharmaceutics-17-00152"><title>2.3. X-Ray Powder Diffraction</title><p>Powder X-ray diffraction data were acquired using a Bruker D8 Advance diffractometer equipped with a Cu tube CuKa1 (&#x003bb; = 1.54056 &#x000c5;), which operates at 40 KV and 40 mA, a Ge (111) monochromator in the incident beam to obtain only CuKa1 radiation, and a LYNXEYE detector. Data acquisition was completed at a scan rate of 0.02&#x000b0;/s.</p></sec><sec id="sec2dot4-pharmaceutics-17-00152"><title>2.4. Differential Thermal Analysis and Thermogravimetric Analysis</title><p>Differential thermal analysis (DTA) and thermogravimetric analysis (TGA) were conducted concurrently using a Shimadzu DTG-60H instrument. The samples were placed in an open alumina pan and heated from room temperature to 500 &#x000b0;C at a rate of 10 &#x000b0;C per minute, under a nitrogen gas flow of 70 mL/min. Alumina powder served as the reference sample, and the data analysis was performed using TA60WS software (version 2.20, Shimadzu Corporation, Kyoto, Japan).</p></sec><sec id="sec2dot5-pharmaceutics-17-00152"><title>2.5. Fourier-Transform Infrared Spectroscopy</title><p>FT-IR spectra of the samples were obtained using a Jasco 6200 FT-IR spectrometer (Jasco Corporation, Ishikawa-machi, Hachioji-shi, Tokyo, Japan), with 256 scans and 4 cm<sup>&#x02212;1</sup> resolution, in the spectral range 4000&#x02013;400 cm<sup>&#x02212;1</sup>. The samples were pre-prepared in the form of KBr disks by the pellet technique.</p></sec><sec id="sec2dot6-pharmaceutics-17-00152"><title>2.6. Crystal Energies and Intermolecular Interaction Computation</title><p>The strength (magnitude) of intermolecular interaction energies and their nature were investigated and calculated using the CrystalExplorer program [<xref rid="B26-pharmaceutics-17-00152" ref-type="bibr">26</xref>]. The computation was completed for the asymmetric units and for their neighboring molecules located at distances shorter than the sum of the van der Waals radii. The interaction energies are represented by a sum of four individual energy terms: electrostatic energy (E<sub>ele</sub>), polarization (E<sub>pol</sub>), dispersion (E<sub>dis</sub>), and the exchange repulsion term (E<sub>rep</sub>) [<xref rid="B27-pharmaceutics-17-00152" ref-type="bibr">27</xref>].</p><p>The energy terms were calculated using the [B3LYP/6-31H(d,p)] level of theory. The following scale factors were considered based on the B3LYP energy model, namely k<sub>ele</sub> = 1.057, k<sub>pol</sub> = 0.740, k<sub>disp</sub> = 0.871, and k<sub>rep</sub> = 0.618.</p><p>The values of crystal lattice energies were evaluated using the CrystalExplorer program [<xref rid="B26-pharmaceutics-17-00152" ref-type="bibr">26</xref>] considering the contributions over a cluster with a radius of 37 &#x000c5; around the asymmetric units.</p><p>The normalized bond lengths were used as follows: CH, CH<sub>2</sub>, and CH<sub>3</sub> groups (C-H = 1.083 &#x000c5;) and O-H distances equal to 0.983 &#x000c5; [<xref rid="B28-pharmaceutics-17-00152" ref-type="bibr">28</xref>].</p></sec><sec id="sec2dot7-pharmaceutics-17-00152"><title>2.7. Stability</title><p>The stability assessment was conducted using the Memmert Humidity Chamber HCP105, which allows the precise control of both relative humidity (having an accuracy of &#x000b1;1% RH) and temperature (having an accuracy of &#x000b1;0.1 &#x000b0;C). Periodically, the samples taken from the chamber were analyzed by X-ray powder diffraction to monitor any potential structural changes.</p></sec><sec id="sec2dot8-pharmaceutics-17-00152"><title>2.8. UV Measurements</title><p>In vitro solubility tests were performed with the Jasco-V-650 Spectrometer (Jasco Corporation, Ishikawa-machi, Hachioji-shi, Tokyo, Japan) using the LV-724 integrating sphere for UV tests on liquids. The dissolution medium of the samples to be analyzed was deionized water (pH = 6). From a quantity of 3 mg of each sample to be investigated, five stock solutions were prepared in water with the excess sample, which was left stirring (100 rpm) at 37 &#x000b0;C &#x000b1; 1 &#x000b0;C. After 48 h, the solutions were filtered through a 0.45 &#x003bc;m syringe filter. The concentration of the substance from each analyzed stock solution was calculated against the total volume of water added to obtain the supersaturated solutions. UV analysis of liquid samples was performed in the wavelength range of 200&#x02013;500 nm, and the sample support was quartz cuvettes (path length 1 cm, V~500 &#x003bc;L).</p></sec></sec><sec sec-type="results" id="sec3-pharmaceutics-17-00152"><title>3. Results</title><sec id="sec3dot1-pharmaceutics-17-00152"><title>3.1. Crystal Structures Descriptions</title><p>The crystallographic and other refinement-related data of the six solid forms investigated by single crystal X-ray diffraction are given in <xref rid="pharmaceutics-17-00152-t001" ref-type="table">Table 1</xref>.</p><sec id="sec3dot1dot1-pharmaceutics-17-00152"><title>3.1.1. GW-6</title><p>The recrystallization of cardarine in methanol yielded the formation of a new polymorph, which was proven to be monoclinic with the centrosymmetric space group P2<sub>1</sub>/n whose asymmetric unit comprises one molecule as depicted in <xref rid="pharmaceutics-17-00152-f001" ref-type="fig">Figure 1</xref>a. The crystal exhibits strong mutual carboxyl&#x000b7;&#x000b7;&#x000b7;carboxyl O3-H3&#x000b7;&#x000b7;&#x000b7;O2 hydrogen bonds depicting a R<sup>2</sup><sub>2</sub>(8) homosynthon. The molecule adopts a twisted shape at the methylsulfanyl moiety. The cohesion is also completed by stacking &#x003c0;&#x000b7;&#x000b7;&#x000b7;&#x003c0; contacts (C21&#x000b7;&#x000b7;&#x000b7;C16 contact, 3.4 &#x000c5;) between the carboxyl group and the phenyl ring and C14-H14&#x000b7;&#x000b7;&#x000b7;F2 interactions of the same phenyl ring with the trifluoromethyl group. The crystal packing diagram observed along the <italic toggle="yes">b</italic>-axis is depicted in <xref rid="pharmaceutics-17-00152-f001" ref-type="fig">Figure 1</xref>b.</p></sec><sec id="sec3dot1dot2-pharmaceutics-17-00152"><title>3.1.2. GW-Bipy</title><p>The slow evaporation of the solvent from a mixture of cardarine and 4,4&#x02032;-bipyridine with various solvents (methanol, ethanol, acetonitrile) led to the self-assembling of a new cocrystal. Using the X-ray diffraction method, it was found to be in a stoichiometric ratio of 2:1 between cardarine to bipyridine and to crystallize in the triclinic crystal system (centrosymmetric P-1 space group) with one cardarine molecule in the asymmetric unit (<xref rid="pharmaceutics-17-00152-f002" ref-type="fig">Figure 2</xref>a) and half a molecule of bipirydine, which is located on special positions (namely inversion centers of the unit cell corners). The cardarine molecule is found in a twisted shape in the methylsulfanyl group (<xref rid="pharmaceutics-17-00152-f002" ref-type="fig">Figure 2</xref>a). Within the asymmetric unit, the hydroxyl group acts as a donor in the formation of strong hydrogen bridges with the nitrogen of bipiridine. Other intermolecular interactions with distances shorter than the sum of van der Waals radii involved in stability are the C17-H17&#x000b7;&#x000b7;&#x000b7;O3 interaction between the phenyl ring and carboxyl group and C26-H26&#x000b7;&#x000b7;&#x000b7;S2 between the phenyl ring and methylsulfanyl moiety. A perspective of crystal packing along the a-axis is illustrated in <xref rid="pharmaceutics-17-00152-f002" ref-type="fig">Figure 2</xref>b.</p></sec><sec id="sec3dot1dot3-pharmaceutics-17-00152"><title>3.1.3. GW-DMF</title><p>The recrystallization of cardarine in a solution of dimethylformamide yielded the formation of a solvate, which embedded dimethylformamide molecules within the lattice found in a stoichiometric ratio of cardarine: dimethylformamide of 1:1. The crystal is triclinic centrosymmetric and belongs to the P-1 space group. The asymmetric unit is depicted in <xref rid="pharmaceutics-17-00152-f003" ref-type="fig">Figure 3</xref>a and displays a ring like R<sup>2</sup><sub>2</sub>(7) graph set motif, which links the cardarine and solvent molecule via hydroxyl&#x000b7;&#x000b7;&#x000b7;carbonyl O3-H&#x000b7;&#x000b7;&#x000b7;O4 and C22-H&#x000b7;&#x000b7;&#x000b7;O2 hydrogen bonds. The formation of supramolecular architectures are also sustained by C7-H&#x000b7;&#x000b7;&#x000b7;O4, C6-H&#x000b7;&#x000b7;&#x000b7;O3, and O3-H3&#x000b7;&#x000b7;&#x000b7;O4 hydrogen bonds, which link two cardarine molecules and one solvent molecule in a R<sup>2</sup><sub>2</sub>(7) motif. The molecular layers of molecules are connected by the solvent molecule, which is linked as well to the C=O carbonyl group of cardarine via the C23-H&#x000b7;&#x000b7;&#x000b7;O2 bond. The molecular packing in the crystal seen along a-axis is depicted in <xref rid="pharmaceutics-17-00152-f003" ref-type="fig">Figure 3</xref>b.</p></sec><sec id="sec3dot1dot4-pharmaceutics-17-00152"><title>3.1.4. GW-MeOH</title><p>The fourth investigated and reported new solid form of cardarine is the methanol solvate, which has formed in a 1:1 stoichiometric ratio as well as its analogous dimethylformamide solvate. The crystal is a monoclinic with P2<sub>1</sub>/c space group with the asymmetric unit being shown in <xref rid="pharmaceutics-17-00152-f004" ref-type="fig">Figure 4</xref>a. Two cardarine and two solvent molecules are bridged via O-H&#x000b7;&#x000b7;&#x000b7;O hydrogen bonds and form a R<sup>4</sup><sub>4</sub>(12) homosynthon. Along the direction of the a-axis, the molecules are stacked via C-H&#x000b7;&#x000b7;&#x000b7;&#x003c0; contact (C20-H20A&#x000b7;&#x000b7;&#x000b7;C17 and C20-H20B&#x000b7;&#x000b7;&#x000b7;O3) interactions (<xref rid="pharmaceutics-17-00152-f004" ref-type="fig">Figure 4</xref>b).</p></sec><sec id="sec3dot1dot5-pharmaceutics-17-00152"><title>3.1.5. GW-SO</title><p>The recrystallization of cardarine in dimethyl sulfoxide yielded to the formation of a new cardarine derivative, which gained an oxygen atom at the S1 sulfur of the methylsulfanyl group; in this way, the valence of S1 is 4 and becomes a sulfoxide group. This transformation involves a thioether (C-S-C) being oxidized to form a sulfoxide (C-SO-C), where one oxygen atom is added to the sulfur. This is a common oxidation process in the pharmaceutical chemistry.</p><p>The asymmetric unit of the newly crystalline form includes two individual such molecules (denoted by A and B suffixes, <xref rid="pharmaceutics-17-00152-f005" ref-type="fig">Figure 5</xref>a). Both molecules depict heavily distorted configurations at the sulfoxide moiety. The layout of supramolecular arrangements is comprised by alternant chains of A and B molecules, which are bridged by carboxyl&#x000b7;&#x000b7;&#x000b7;sulfoxide (O3B-H3B&#x000b7;&#x000b7;O4B and O3A-H3A&#x000b7;&#x000b7;&#x000b7;O4A) (<xref rid="pharmaceutics-17-00152-f005" ref-type="fig">Figure 5</xref>b). Between these molecular chains, C-H&#x000b7;&#x000b7;&#x000b7;&#x003c0; (C12A-H12C&#x000b7;&#x000b7;&#x000b7;C3B) and C-H&#x000b7;&#x000b7;&#x000b7;F interactions (C11A-H11E&#x000b7;&#x000b7;&#x000b7;F1A and C12B-H12A&#x000b7;&#x000b7;&#x000b7;F2B) take place.</p></sec><sec id="sec3dot1dot6-pharmaceutics-17-00152"><title>3.1.6. GW-SO<sub>2</sub></title><p>Another derivative was obtained by recrystallization in a mixture of nitromethane, which is dioxidized at the methylsulfanyl S2 sulfur, thus gaining two oxygen atoms and the valence of sulfur becomes 6. The transformation involves a sulfur atom with two carbons attached (a thioether group, C-S-C) being oxidized to a sulfonyl group (C-SO<sub>2</sub>-C), where two oxygen atoms are added to the sulfur atom. This is a process called oxidation of a thioether to a sulfone (SO<sub>2</sub>) group.</p><p>The asymmetric unit is displayed in <xref rid="pharmaceutics-17-00152-f006" ref-type="fig">Figure 6</xref>a, showing the molecule adopting a slightly twisted geometry at the methylsulfanyl group. Unlike in the cases of the other crystals where the thiazole ring was not involved in hydrogen bonding, in dioxidized GW-SO<sub>2</sub>, the carboxyl group is bridged to the nitrogen of the thiazole ring by O3-H3&#x000b7;&#x000b7;N1 bonds, which are extended in the direction of the ob-axis. The crystal packing along the ao-axis is depicted in <xref rid="pharmaceutics-17-00152-f006" ref-type="fig">Figure 6</xref>b.</p><p>The packing and molecular drawings of the studied crystals were generated using Mercury software (Version 2023 3.0) [<xref rid="B29-pharmaceutics-17-00152" ref-type="bibr">29</xref>]. The intermolecular contacts with distances shorter or equal with the van der Waals radii are listed in <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Table S1 (Supporting Information)</xref>.</p><p>The conclusions made based on the analysis of the new crystalline forms are as follows:<list list-type="simple"><list-item><label>(i)</label><p>Cardarine shows a high yield in being prepared in the form of new crystalline forms and derivatives mostly due to the high molecular flexibility exhibited at the methylsulfanyl group (carbon-sulfur C12-S2 bond) due to the involvement of the OH group in the formation of new hydrogen bonds and the embedding of guest molecules;</p></list-item><list-item><label>(ii)</label><p>All six crystals are centrosymmetric and either monoclinic or triclinic;</p></list-item><list-item><label>(iii)</label><p>Supramolecular self-assemblies are driven by strong O-H&#x000b7;&#x000b7;&#x000b7;O and O-H&#x000b7;&#x000b7;&#x000b7;N hydrogen bonds involving the carboxyl COOH group and the thiazole ring and other van der Waals interactions such as C-H&#x000b7;&#x000b7;&#x000b7;O, C-H&#x000b7;&#x000b7;&#x000b7;&#x003c0;, and C-H&#x000b7;&#x000b7;&#x000b7;F;</p></list-item><list-item><label>(iv)</label><p>The polymorph exhibits self-assembly synthons of the R<sup>2</sup><sub>2</sub>(8) type, the GW-DMF solvate has two R<sup>2</sup><sub>2</sub>(7) synthons, and the GW-MeOH solvate forms an R<sup>4</sup><sub>4</sub>(12) type synthon.</p></list-item></list></p></sec></sec><sec id="sec3dot2-pharmaceutics-17-00152"><title>3.2. Powder X-Ray Diffraction Analysis</title><p>The X-ray diffraction analysis was conducted with the purpose of checking the structural homogeneity, the purity of the prepared samples, and the proof that the analyzed single crystals are representative of the entire bulk of powder samples. The comparisons of simulated diffraction patterns (which were generated based on the CIF files) and the experimental patterns are illustrated in <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S1 (Supporting Information)</xref>. A good match in all paired comparisons can be noticed, with the exception of some diffraction intensities, which are lower in the experimental ones and which account for the preferred orientation of crystallites.</p></sec><sec id="sec3dot3-pharmaceutics-17-00152"><title>3.3. DTA/TGA Thermal Analysis</title><p>Simultaneous DTA/TGA analysis established the thermal characteristics of the new solid forms obtained with cardarine; the curves are illustrated in <xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>a&#x02013;f.</p><p>For the GW-6 (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>a), an endothermic peak at ~101 &#x000b0;C is assigned to the heat absorbed by the sample during the process of phase transition in a new phase (most likely a new polymorphic phase). Shortly after this event, a small exothermic peak appears at ~105 &#x000b0;C, which can be explained by the crystallization process and the rearrangement of cardarine molecules in the lattice. The two endothermic signals with a maximum at ~130 and 134 &#x000b0;C are attributed to the melting event of cardarine.</p><p>The DTA trace of GW-MeOH (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>b) exhibits a sharp endothermic peak at 84 &#x000b0;C, which can be attributed to the loss of methanol molecules found within the crystal lattice, which is accompanied by the TGA graph with an experimental mass loss of 5% due to the loss of methanol molecules, which is quite close to the theoretical solvent content of 6.59%. The slight difference of roughly 1.5% could possibly be due to the fact that not all cardarine molecules within the sample have an associated guest methanol molecule embedded within the lattice; hence, it results in a slightly lower mass loss on the experimental data. At ~104 &#x000b0;C, a small exothermic peak can be noticed, which corresponds to the rearrangement and crystallization of the cardarine molecules, which further undergo the melting process in two steps evidenced by the two endothermic peaks at ~121 &#x000b0;C and 135 &#x000b0;C.</p><p>The DTA diagram of the GW-DMF (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>c) solvate manifests a sharp endothermic signal at ~91 &#x000b0;C, which corresponds to the loss of dimethylformamide molecules embedded within the lattice and is accompanied by an experimental mass loss of 8.2% and 5.6%, which accounts for the mass of lost solvent molecules, being exactly the same as the theoretical mass assigned to DMF molecules, which accounts for 13.8% of the total mass. The melting of the cardarine molecules that are left occurs in two steps and is seen as a small endothermic signal at ~133 &#x000b0;C and a sharp protruding endotherm at ~144 &#x000b0;C.</p><p>The DTA curve of the cocrystal multicomponent 2:1 ratio of GW-bipy adduct (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>d) shows an endothermic signal with a maximum value at ~123 &#x000b0;C, which is associated with the melting of the multicomponent cardarine-bipyridine system. With increasing heating of the sample, the first weight loss of 21.5% occurs from 140 to 275 &#x000b0;C, which corresponded to the loss of the 4,4&#x02032;-bipyridine molecules from the melt.</p><p>To prove that the cocrystal with 4,4 bipyridine (GW-bipy) has a different thermal behavior compared to the pure coformer (bipyridine), the DTA/TGA curves for it were also recorded (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>d).</p><p>The endothermic peak observed in the DTA curve of bipyridine at ~75 &#x000b0;C is attributed to the evaporation of water absorbed on the surface and is accompanied by a mass loss of 8.3%. Furthermore, the sharp peak at ~112 &#x000b0;C is associated with the melting of bipyridine (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>e). Its degradation was evidenced by an endothermic signal with a maximum at ~189 &#x000b0;C, being accompanied by a mass loss of 91.6%. Previous studies have also reported similar thermal behavior for 4,4&#x02032;-bipyridine [<xref rid="B30-pharmaceutics-17-00152" ref-type="bibr">30</xref>]. Thus, in the case of pure bipyridine, the mass loss occurs in the temperature range of 111&#x02013;200 &#x000b0;C, and in the case of the cocrystal, the mass loss due to 4,4&#x02032;-bipyridine occurs approximately between 130 and 280 &#x000b0;C. Similar thermal analysis was reported in the case of baicalein based cocrystal with 4,4&#x02032;-bipyridine [<xref rid="B31-pharmaceutics-17-00152" ref-type="bibr">31</xref>].</p><p>From the comparison of the values of the temperature at which the melting of cardarine (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>a) takes place, it can be observed that in the cocrystal (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>c), the event associated with melting occurs at a higher value than in bipyridine (<xref rid="pharmaceutics-17-00152-f007" ref-type="fig">Figure 7</xref>d) and lower than in the starting cardarine. This is the consequence of the co-crystal formation between cardarine and 4,4&#x02032;-bipyridine.</p><p>From the comparison of the temperatures at which the thermal events take place, it can be observed that all new solid forms exhibit similar behavior in terms of degradation and oxidation, which occurs at 294 &#x000b0;C for GW-polymorph, 281 &#x000b0;C and 290.5 &#x000b0;C for GW-MeOH, 294 &#x000b0;C for GW-Bipy, and 303 &#x000b0;C for GW-DMF. These processes are also accompanied by a great mass loss of over 50% of the total mass.</p><p>The melting process that occurs in successive steps with small temperature differences between the steps (GW-6, GW-MeOH and GW-DMF) can be explained by a partial melting of the compound, followed immediately by a minor structural rearrangement before melting completely.</p><p>In <xref rid="pharmaceutics-17-00152-t002" ref-type="table">Table 2</xref>, the values of melting points that are further compared with the ones of the five polymorphs reported previously are summarized (GW-1 to GW-5) [<xref rid="B11-pharmaceutics-17-00152" ref-type="bibr">11</xref>]. It can be noted that the melting point of the new polymorph (GW-6) is comparable with the other, while the inclusion of guest molecules (GW-MeOH, GW-DMF, and GW-Bipy) led to a slight decrease in the melting points values overall.</p></sec><sec id="sec3dot4-pharmaceutics-17-00152"><title>3.4. Crystal Lattice Energies and Pairwise Intermolecular Energies Evaluation</title><p>The lattice energies for the six novel crystals, along with their individual lattice term breakdowns, are presented in <xref rid="pharmaceutics-17-00152-t003" ref-type="table">Table 3</xref>.</p><p>With reference to the newly reported polymorph, a total lattice energy of &#x02212;233.3 kJ/mol is displayed, which is comparable with the other five cardarine polymorphs already reported, which are found between &#x02212;195.7 kJ/mol and &#x02212;236.8 kJ/mol [<xref rid="B11-pharmaceutics-17-00152" ref-type="bibr">11</xref>], which suggests a similar overall stability.</p><p>The 2:1 cocrystal with bipyridine shows an overall energy of &#x02212;151.4 kJ/mol, which is lower compared to the polymorph and indicates a lower stability.</p><p>Furthermore, it can be noted that the inclusion of solvent molecules within the lattice lowers the crystal stability, with the computed lattice energies being &#x02212;152.7 kJ/mol for the methanol solvate (GW-MeOH) and with the dimethylformamide solvate (GW-DMF) being slightly more stable with an energy of &#x02013;169.9 kJ/mol.</p><p>The evaluation of the lattice energies can explain the crystallization of cardarine under the two oxidized forms, thus achieving, from a thermodynamic point of view, new configurations with lower energies compared with the multi-component, especially in the doubly oxidized case (&#x02212;260.2 kJ/mol in GW-SO<sub>2</sub>), while the oxidized (GW-SO) has a lattice energy of &#x02212;211.1 kJ/mol only once.</p><p>It can be observed that in mono-component crystals, the weight of the electrostatic attraction term plays a more important role in stability among all the attraction terms, representing approximately 33% of the total lattice energy in GW-6, 50% in GW-SO, and 41% in GW-SO<sub>2</sub>. The dominant term in all the structures is by far the dispersion term, which is also reflected by the molecular arrangement in the crystal.</p><p>Since we were not able to further reproduce the two oxidized cardarine forms (GW-SO and GW-SO<sub>2</sub> derivatives) and to evaluate other properties, besides their crystal structures, the conclusion can only be made based on the evaluation of lattice energies. They are more stable compared to the other multi-component solid forms.</p><p>The analysis of crystal packing is completed based on the calculation of intermolecular interaction energies with neighboring molecules found at distances shorter or equal than the sum of van der Waals radii. The total interaction energies and the breakdown in four separated terms (E<sub>ele</sub>-electrostatic, E<sub>pol</sub>-polarization, E<sub>dis</sub>-dispersion, E<sub>rep</sub>-repulsion) are given in <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Table S2 (Supporting Information)</xref>.</p><p>Conclusions emerging from the analysis of energy values are presented below, as follows:<list list-type="simple"><list-item><label>(i)</label><p>The polymorph is the only structure that displays mutual carboxyl&#x000b7;&#x000b7;&#x000b7;carboxyl O-H&#x000b7;&#x000b7;&#x000b7;O hydrogen bonds and is characterized by a higher magnitude of binding energy compared to other crystals mainly due to its electrostatic nature (E<sub>tot</sub> = &#x02212;126.2 kJ);</p></list-item><list-item><label>(ii)</label><p>The interactions between host&#x02013;guest molecules within the asymmetric units are significant and dominated by the electrostatic terms GW-MeOH (E<sub>tot</sub> = &#x02212;85.4 kJ and E<sub>ele</sub> = &#x02212;65.9 kJ/mol), GW-DMF (E<sub>tot</sub> = &#x02212;110.4 kJ/mol and E<sub>ele</sub> = &#x02212;88.3 kJ/mol), and GW-Bipy (E<sub>tot</sub> = &#x02212;82.2 kJ/mol and E<sub>ele</sub> &#x02212;57.0 kJ/mol);</p></list-item><list-item><label>(iii)</label><p>The GW-SO<sub>2</sub> crystal, which is the only displaying hydroxyl&#x000b7;&#x000b7;&#x000b7;thiazole hydrogen bond, is characterized by a rather high interaction energy (E<sub>tot</sub> = &#x02212;79.7 kJ/mol), which is dominated by the electrostatic component as well (E<sub>ele</sub> = &#x02212;51.6 kJ/mol);</p></list-item><list-item><label>(iv)</label><p>In all of the molecular interaction pairs, the polarization energy has the least representative role in cohesion, which indicates that the molecules are not polarized;</p></list-item><list-item><label>(v)</label><p>A high contribution to the overall stability is given by dispersion energy, which includes the stacking C-H&#x000b7;&#x000b7;&#x000b7;&#x003c0; interactions.</p></list-item></list></p></sec><sec id="sec3dot5-pharmaceutics-17-00152"><title>3.5. FT-IR Spectroscopy</title><p>By analyzing the compounds through FT-IR spectroscopy, the changes in the vibrational frequencies in the new solid forms obtained were highlighted as a result of the formation of hydrogen bonds, either intra or intermolecular. <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S2a,b (Supporting Information)</xref> showed the infrared spectra for the polymorph, the cocrystal, and the two solvates in comparison.</p><p>The spectrum of the multi-component adducts shows a broad absorption band with a peak at 3431 cm<sup>&#x02212;1</sup> in GW-MeOH, at 3487 cm<sup>&#x02212;1</sup> in GW-DMF, and at 3440 cm<sup>&#x02212;1</sup> in the 2:1 GW-Bipy cocrystal due to the stretching vibration of the &#x003c5;(O-H) bond of carboxyl group present in cardarine molecules. It is interesting to note that the same band is not visible in the GW-6.</p><p>The absorption bands in the 3100&#x02013;2800 cm<sup>&#x02212;1</sup> spectral range are due to the stretching vibration of the &#x003c5;(C-H) bonds in the benzene ring and in the CH<sub>3</sub> groups as well.</p><p>The bands that appear between 2600 and 2500 cm<sup>&#x02212;1</sup> correspond to the stretching vibration of the &#x003c5;(S-H) bond. Even though the S-H group is not present in the molecular composition of cardarine and has not been located by single crystal X-ray diffraction, it is likely that the hydrogen from the carboxyl group COOH migrates to the sulfur S2 and this hydrogen atom is attached to the sulfur in a disordered manner. This explained the lack of the specific O-H stretching in the spectra of the GW-polymorph.</p><p>The bands at 1751 cm<sup>&#x02212;1</sup> for GW-polymorph, 1780 cm<sup>&#x02212;1</sup> for GW-Bipy, 1751 cm<sup>&#x02212;1</sup> for GW-MeOH, and 1754 cm<sup>&#x02212;1</sup> for GW-DMF are manifested due to the presence of the carbonyl C=O group.</p><p>Furthermore, at lower wavenumbers (between 1600 and 1650 cm<sup>&#x02212;1</sup>), the bands can be explained by the presence of C=C bonds within the six-membered phenyl rings.</p><p>Between 1550 and 1400 cm<sup>&#x02212;1</sup> in all structures, a low-intensity band associated with the vibration of the stretching C=N group from the thiazole ring can be observed in all spectra.</p><p>The bands observed between 1380 and 1000 are due to the vibration of the stretching (C-F) group [<xref rid="B32-pharmaceutics-17-00152" ref-type="bibr">32</xref>].</p><p>In the spectrum of the cocrystal, in addition to the characteristic vibrations from cardarine commented above, a new vibration at 2462 cm<sup>&#x02212;1</sup> is observed due to the vibration of the pyridine ring from 4,4&#x02032;-bipyridine linked by hydrogen bonding to the cardarine molecule. From the comparison of the spectrum of the cocrystal with the spectra of the starting compounds (<xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S4a,b</xref>), it was observed that the vibration of the O-H stretching bond from bipyridines appears in the cocrystal at a higher value at 3450 cm<sup>&#x02212;1</sup>. The wide peak from 2462 cm<sup>&#x02212;1</sup> is associated with the stretching (S-H) vibration.</p></sec><sec id="sec3dot6-pharmaceutics-17-00152"><title>3.6. In Vitro Solubility Assessment</title><p>A volume of approximately 500 &#x000b5;L of each stock solution was placed in quartz and analyzed in the wavelength range of 200&#x02013;500 nm (<xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S3, Supplementary Information</xref>).</p><p>From the superposed of the UV curves, it can be observed that the starting form of cardarine, the new polymorph, cocrystal, and its solvates show an absorbance maximum at a wavelength of approximately 317 nm.</p><p>Regarding the absorbance, the highest value recorded is in the spectrum of the cocrystal, followed by the methanol solvate. The UV curve recorded for the cocrystal shows two absorption maxima: the first maximum at 235.5 nm, which is due to the presence of 4,4&#x02032;-bipyridine, and the second maximum at 317 nm, which is associated with the cardarine signal. These results indicate that after combining with 4,4&#x02019;-bipyridine molecules, the conformation of cardarine is changed by making hydrogen bonds, leading to an increase in solubility.</p><p>Quantitative calibration and analyses: to plot calibration curves, stock solutions of each compound were diluted with water in various concentrations so that the final volume was 1 mL. The values of the obtained concentrations were calculated in mg/mL and are shown in <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Table S3 (Supplementary Information)</xref>. The calibration curves are shown comparatively in <xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S3 (Supplementary Information)</xref>.</p><p>Based on the calibration curves obtained for each investigated compound, the concentrations at three dilutions of the stock solution of each compound were calculated. The quantitative analysis was carried out for the same wavelength &#x0028e; = 317 nm.</p><p>The calculated values of the concentration of the filtered solutions at which the absorbance is maximum are the following: A<sub>GW</sub> = 0.81, C<sub>GW</sub> = 0.070 mg/mL; A<sub>GW-polymprph</sub> = 0.95, C<sub>GW-6</sub> = 0.06 mg/mL; A<sub>GW-bipy</sub> = 1.05, C<sub>GW-bipy</sub> = 0.072 mg/mL; A<sub>GW-MeOH</sub> = 1.10, C<sub>GW-MeOH</sub> = 0.075 mg/mL; A<sub>GW-DMF</sub> = 0.96, C<sub>GW-DMF</sub> = 0.079 mg/mL. The difference between the experimental value calculated for the stock solution of the samples and the value obtained using the calibration curve is about 0.005 mg/mL, which represents the mass of the undissolved substance that remained in the syringe filter. From the results of the UV tests, it can be observed that by preparing a new cardarine polymorph, its solubility is slightly lower compared to solvates or the cocrystal.</p></sec><sec id="sec3dot7-pharmaceutics-17-00152"><title>3.7. Stability of the Polymorph and the Cocrystal</title><p>The stability of a specific polymorphic form or a cocrystal may be viewed as a disadvantage, as potential phase transitions between polymorphs during extended storage can alter the drug&#x02019;s physical state, subsequently affecting its shelf life and efficacy. Consequently, it is essential to store the polymorphs in a controlled environment where they are subjected to specific humidity and temperature conditions (75% relative humidity and 40 &#x000b0;C) in order to assess their stability.</p><p>The new polymorph and the 2:1 cocrystal samples were stored for up to three months in the climatic chamber and the powder X-ray diffraction patterns were recorded at six-week and three-month intervals, respectively. No significant structural changes occurred in the meantime with the exception that the samples became slightly more amorphous, which indicates that the samples are stable and did not suffer phase transitions (<xref rid="app1-pharmaceutics-17-00152" ref-type="app">Figure S4, Supporting Information</xref>).</p></sec></sec><sec sec-type="conclusions" id="sec4-pharmaceutics-17-00152"><title>4. Conclusions</title><p>The crystal structures of the four new cardarine-based solid forms and two chemically modified structures were determined and reported. The GW-6, the GW-MeOH, and the GW-SO<sub>2</sub> forms are centrosymmetric and monoclinic crystals while the GW-bipy, the GW-DMF solvate. and the GW-SO are centrosymmetric triclinic crystals. By the use of the COOH carboxyl group and coupled with the great flexibility at the methylsulfanyl moiety, it was demonstrated that cardarine shows a high potential to be prepared and obtained in the form of new solid forms.</p><p>The stability of the crystals is primarily maintained by strong O-H&#x000b7;&#x000b7;&#x000b7;N hydrogen bonds between the carboxyl and thiazole rings, as well as reciprocal O-H&#x000b7;&#x000b7;&#x000b7;O hydrogen bonds between carboxyl groups, which make a significant contribution to the electrostatic interaction energy. Another key factor in crystal cohesion is the dispersion interactions, with C-H&#x000b7;&#x000b7;&#x000b7;&#x003c0; contacts playing the most prominent role in this aspect.</p><p>The DTA/TGA analysis has explored the formation of the new multicomponent crystals and assigned their thermal behavior in terms of loss of embedded solvent molecules, the phase transitions that occur for the polymorph, and the methanol solvate before their melting points.</p><p>The polymorph and the bipyridine cocrystal are stable and do not undergo phase transitions while the evaluation of their solubility showed a slight improvement for the cocrystal and both solvates compared to the starting form while the solubility of the new polymorph is slightly lower.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-pharmaceutics-17-00152"><title>Supplementary Materials</title><p>CIF files of the cardarine-based crystals were deposited via the Cambridge Crystallographic Data Centre: 2406160 (GW-6); 2406161(GW-Bipy); 2406162 (GW-MeOH); 2406163 (GW-DMF); 2406164 (GW-SO); and 2406165 (GW-SO<sub>2</sub>). The copies can be obtained free of charge on written application to CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax: +44-1223-336033); on request via e-mail to <email>deposit@ccdc.cam.uk</email>; or by access to <uri xlink:href="http://www.ccdc.cam.ac.uk">http://www.ccdc.cam.ac.uk</uri> (accessed on 22 January 2025). The following supporting information can be downloaded at <uri xlink:href="https://www.mdpi.com/article/10.3390/pharmaceutics17020152/s1">https://www.mdpi.com/article/10.3390/pharmaceutics17020152/s1</uri>: Figure S1: Experimental and simulated powder X-ray diffraction patterns for the new cardarine-based solid forms and derivatives: GW-6 (a), GW-Bipy (b), GW-MeOH (c), GW-DMF (d), GW-SO (e), GW-SO<sub>2</sub> (f); Figure S2: FTIR spectra in the 2000&#x02013;4000 cm<sup>&#x02212;1</sup> range (a) and 400&#x02013;2000 cm<sup>&#x02212;1</sup> (b); Figure S3: UV spectra of the cardarine-based solid forms and calibration curves; Figure S4: Diffraction patterns of the polymorph (a) and 2:1 cocrystal (b) kept in the climatic chamber; Table S1: Intermolecular interactions shorter than the sum of van der Waals radii (&#x000c5;, <sup>o</sup>); Table S2: Nature and magnitudes of intermolecular interaction energies for selected intermolecular contacts (kJ/mol); Table S3: The concentrations of the solutions used to determine the calibration curves.</p><supplementary-material id="pharmaceutics-17-00152-s001" position="float" content-type="local-data"><media xlink:href="pharmaceutics-17-00152-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, A.T., L.M., and G.B.; methodology, G.B.; software, A.T. and L.M.; validation, A.T., M.B., M.M.-P., L.M., G.B., and V.P.; formal analysis, V.P.; investigation, M.M.-P., M.B., and L.M.; resources, G.B. and V.P.; data curation, A.T. and L.M.; writing&#x02014;original draft preparation, A.T. and G.B.; writing&#x02014;review and editing, A.T.; visualization, V.P.; supervision, V.P.; project administration, G.B.; funding acquisition, V.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>On request via email to <email>alexandru.turza@itim-cj.ro</email>.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-17-00152"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Terada</surname><given-names>M.</given-names></name>
<name><surname>Araki</surname><given-names>M.</given-names></name>
<name><surname>Ashibe</surname><given-names>B.</given-names></name>
<name><surname>Motojima</surname><given-names>K.</given-names></name>
</person-group><article-title>GW501516 acts as an efficient PPAR&#x003b1; activator in the mouse liver</article-title><source>Drug Discov. Ther.</source><year>2011</year><volume>5</volume><fpage>176</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.5582/ddt.2011.v5.4.176</pub-id><pub-id pub-id-type="pmid">22466297</pub-id>
</element-citation></ref><ref id="B2-pharmaceutics-17-00152"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brunmair</surname><given-names>B.</given-names></name>
<name><surname>Staniek</surname><given-names>K.</given-names></name>
<name><surname>D&#x000f6;rig</surname><given-names>J.</given-names></name>
<name><surname>Sz&#x000f6;cs</surname><given-names>Z.</given-names></name>
<name><surname>Stadlbauer</surname><given-names>K.</given-names></name>
<name><surname>Marian</surname><given-names>V.</given-names></name>
<name><surname>Gras</surname><given-names>F.</given-names></name>
<name><surname>Anderwald</surname><given-names>C.</given-names></name>
<name><surname>Nohl</surname><given-names>H.</given-names></name>
<name><surname>F&#x000fc;rnsinn</surname><given-names>W.W.</given-names></name>
<etal/>
</person-group><article-title>Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids</article-title><source>Diabetologia</source><year>2006</year><volume>49</volume><fpage>2713</fpage><lpage>2722</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0357-6</pub-id><pub-id pub-id-type="pmid">16960684</pub-id>
</element-citation></ref><ref id="B3-pharmaceutics-17-00152"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dressel</surname><given-names>U.</given-names></name>
<name><surname>Allen</surname><given-names>T.L.</given-names></name>
<name><surname>Pippal</surname><given-names>J.B.</given-names></name>
<name><surname>Rohde</surname><given-names>P.R.</given-names></name>
<name><surname>Lau</surname><given-names>P.</given-names></name>
<name><surname>Muscat</surname><given-names>G.E.</given-names></name>
</person-group><article-title>The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells</article-title><source>Mol. Endocrinol.</source><year>2003</year><volume>17</volume><fpage>2477</fpage><lpage>2493</lpage><pub-id pub-id-type="doi">10.1210/me.2003-0151</pub-id><pub-id pub-id-type="pmid">14525954</pub-id>
</element-citation></ref><ref id="B4-pharmaceutics-17-00152"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kintz</surname><given-names>P.</given-names></name>
<name><surname>Gheddar</surname><given-names>L.</given-names></name>
<name><surname>Paradis</surname><given-names>C.</given-names></name>
<name><surname>Chinellato</surname><given-names>M.</given-names></name>
<name><surname>Ameline</surname><given-names>A.</given-names></name>
<name><surname>Raul</surname><given-names>J.S.</given-names></name>
<name><surname>Oliva-Labadie</surname><given-names>M.</given-names></name>
</person-group><article-title>Peroxisome Proliferator-Activated Receptor Delta Agonist (PPAR-&#x003b4;) and Selective Androgen Receptor Modulator (SARM) Abuse: Clinical, Analytical and Biological Data in a Case Involving a Poisonous Combination of GW1516 (Cardarine) and MK2866 (Ostarine)</article-title><source>Toxics</source><year>2021</year><volume>9</volume><elocation-id>251</elocation-id><pub-id pub-id-type="doi">10.3390/toxics9100251</pub-id><pub-id pub-id-type="pmid">34678947</pub-id>
</element-citation></ref><ref id="B5-pharmaceutics-17-00152"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barish</surname><given-names>G.D.</given-names></name>
<name><surname>Narkar</surname><given-names>V.A.</given-names></name>
<name><surname>Evans</surname><given-names>R.M.</given-names></name>
</person-group><article-title>PPAR delta: A dagger in the heart of the metabolic syndrome</article-title><source>J. Clin. Investig.</source><year>2006</year><volume>116</volume><fpage>590</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1172/JCI27955</pub-id><pub-id pub-id-type="pmid">16511591</pub-id>
</element-citation></ref><ref id="B6-pharmaceutics-17-00152"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coll</surname><given-names>T.</given-names></name>
<name><surname>Alvarez-Guardia</surname><given-names>D.</given-names></name>
<name><surname>Barroso</surname><given-names>E.</given-names></name>
<name><surname>G&#x000f3;mez-Foix</surname><given-names>A.M.</given-names></name>
<name><surname>Palomer</surname><given-names>X.</given-names></name>
<name><surname>Laguna</surname><given-names>J.C.</given-names></name>
<name><surname>V&#x000e1;zquez-Carrera</surname><given-names>M.</given-names></name>
</person-group><article-title>Activation of peroxisome proliferator-activated receptor-&#x003b4; by GW501516 prevents fatty acid-induced nuclear factor-&#x003ba;B activation and insulin resistance in skeletal muscle cells</article-title><source>Endocrinology</source><year>2010</year><volume>151</volume><fpage>1560</fpage><lpage>1569</lpage><pub-id pub-id-type="doi">10.1210/en.2009-1211</pub-id><pub-id pub-id-type="pmid">20185762</pub-id>
</element-citation></ref><ref id="B7-pharmaceutics-17-00152"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Paw</surname><given-names>M.</given-names></name>
<name><surname>Wnuk</surname><given-names>D.</given-names></name>
<name><surname>Madeja</surname><given-names>Z.</given-names></name>
<name><surname>Michalik</surname><given-names>M.</given-names></name>
</person-group><article-title>PPAR&#x003b4; Agonist GW501516 Suppresses the TGF-&#x003b2;-Induced Profibrotic Response of Human Bronchial Fibroblasts from Asthmatic Patients</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>7721</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24097721</pub-id><pub-id pub-id-type="pmid">37175437</pub-id>
</element-citation></ref><ref id="B8-pharmaceutics-17-00152"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kintz</surname><given-names>P.</given-names></name>
<name><surname>Ameline</surname><given-names>A.</given-names></name>
<name><surname>Gheddar</surname><given-names>L.</given-names></name>
<name><surname>Raul</surname><given-names>J.-S.</given-names></name>
</person-group><article-title>Testing for G W501516 (cardarine) in human hair using LC/MS- MS and confirmation by LC/HRMS</article-title><source>Drug Test Anal.</source><year>2020</year><volume>12</volume><fpage>980</fpage><lpage>986</lpage><pub-id pub-id-type="doi">10.1002/dta.2802</pub-id><pub-id pub-id-type="pmid">32298044</pub-id>
</element-citation></ref><ref id="B9-pharmaceutics-17-00152"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Weihrauch</surname><given-names>M.</given-names></name>
<name><surname>Handschin</surname><given-names>C.</given-names></name>
</person-group><article-title>Pharmacological targeting of exercise adaptations in skeletal muscle: Benefits and pitfalls</article-title><source>Biochem. Pharmacol.</source><year>2018</year><volume>147</volume><fpage>211</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2017.10.006</pub-id><pub-id pub-id-type="pmid">29061342</pub-id>
</element-citation></ref><ref id="B10-pharmaceutics-17-00152"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Trevisiol</surname><given-names>S.</given-names></name>
<name><surname>Moulard</surname><given-names>Y.</given-names></name>
<name><surname>Delcourt</surname><given-names>V.</given-names></name>
<name><surname>Jaubert</surname><given-names>M.</given-names></name>
<name><surname>Boyer</surname><given-names>S.</given-names></name>
<name><surname>Tendon</surname><given-names>S.</given-names></name>
<name><surname>Haryouli</surname><given-names>H.</given-names></name>
<name><surname>Taleb</surname><given-names>W.</given-names></name>
<name><surname>Caroff</surname><given-names>M.</given-names></name>
<name><surname>Chabot</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Comprehensive characterization of peroxisome proliferator activated receptor-&#x003b4; agonist GW501516 for horse doping control analysis</article-title><source>Drug Test. Anal.</source><year>2021</year><volume>13</volume><fpage>1191</fpage><lpage>1202</lpage><pub-id pub-id-type="doi">10.1002/dta.3013</pub-id><pub-id pub-id-type="pmid">33547737</pub-id>
</element-citation></ref><ref id="B11-pharmaceutics-17-00152"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turza</surname><given-names>A.</given-names></name>
<name><surname>Pascuta</surname><given-names>P.</given-names></name>
<name><surname>Muresan-Pop</surname><given-names>M.</given-names></name>
<name><surname>Mare</surname><given-names>L.</given-names></name>
<name><surname>Borodi</surname><given-names>G.</given-names></name>
<name><surname>Popescu</surname><given-names>V.</given-names></name>
</person-group><article-title>Five Novel Polymorphs of Cardarine/GW501516 and Their Characterization by X-ray Diffraction, Computational Methods, Thermal Analysis and a Pharmaceutical Perspective</article-title><source>Pharmaceutics</source><year>2024</year><volume>16</volume><elocation-id>623</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics16050623</pub-id><pub-id pub-id-type="pmid">38794285</pub-id>
</element-citation></ref><ref id="B12-pharmaceutics-17-00152"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Groom</surname><given-names>C.R.</given-names></name>
<name><surname>Bruno</surname><given-names>I.J.</given-names></name>
<name><surname>Lightfoot</surname><given-names>M.P.</given-names></name>
<name><surname>Ward</surname><given-names>S.C.</given-names></name>
</person-group><article-title>The Cambridge Structural Database</article-title><source>Acta Cryst.</source><year>2016</year><volume>72</volume><fpage>171</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1107/S2052520616003954</pub-id><pub-id pub-id-type="pmid">27048719</pub-id>
</element-citation></ref><ref id="B13-pharmaceutics-17-00152"><label>13.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Bernstein</surname><given-names>J.</given-names></name>
</person-group><source>Polymorphism in Molecular Crystals</source><publisher-name>Oxford University Press</publisher-name><publisher-loc>Oxford, UK</publisher-loc><year>2002</year></element-citation></ref><ref id="B14-pharmaceutics-17-00152"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chistyakov</surname><given-names>D.</given-names></name>
<name><surname>Sergeev</surname><given-names>G.</given-names></name>
</person-group><article-title>The Polymorphism of Drugs: New Approaches to the Synthesis of Nanostructured Polymorphs</article-title><source>Pharmaceutics</source><year>2020</year><volume>12</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics12010034</pub-id><pub-id pub-id-type="pmid">31906357</pub-id>
</element-citation></ref><ref id="B15-pharmaceutics-17-00152"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Turza</surname><given-names>A.</given-names></name>
<name><surname>Borodi</surname><given-names>G.</given-names></name>
<name><surname>Miclaus</surname><given-names>M.</given-names></name>
<name><surname>Muresan-Pop</surname><given-names>M.</given-names></name>
</person-group><article-title>Exploring the polymorphism of selective androgen receptor modulator YK11</article-title><source>J. Mol. Struct.</source><year>2023</year><volume>1273</volume><fpage>134281</fpage><pub-id pub-id-type="doi">10.1016/j.molstruc.2022.134281</pub-id></element-citation></ref><ref id="B16-pharmaceutics-17-00152"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vippagunta</surname><given-names>S.R.</given-names></name>
<name><surname>Brittain</surname><given-names>H.G.</given-names></name>
<name><surname>Grant</surname><given-names>D.J.W.</given-names></name>
</person-group><article-title>Crystalline solids</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>48</volume><fpage>3</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00097-7</pub-id><pub-id pub-id-type="pmid">11325474</pub-id>
</element-citation></ref><ref id="B17-pharmaceutics-17-00152"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>F.</given-names></name>
<name><surname>Pop</surname><given-names>M.</given-names></name>
<name><surname>Kacso</surname><given-names>I.</given-names></name>
<name><surname>Grosu</surname><given-names>I.G.</given-names></name>
<name><surname>Micl&#x00103;u&#x0015f;</surname><given-names>M.</given-names></name>
<name><surname>Vodnar</surname><given-names>I.L.</given-names></name>
<name><surname>Filip</surname><given-names>G.A.</given-names></name>
<name><surname>Olteanu</surname><given-names>E.D.</given-names></name>
<name><surname>Moldovan</surname><given-names>R.</given-names></name>
<name><surname>Nagy</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Ketoconazole-p-aminobenzoic Acid Cocrystal: Revival of an Old Drug by Crystal Engineering</article-title><source>Mol. Pharm.</source><year>2020</year><volume>17</volume><fpage>919</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01178</pub-id><pub-id pub-id-type="pmid">31986050</pub-id>
</element-citation></ref><ref id="B18-pharmaceutics-17-00152"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grosu</surname><given-names>I.G.</given-names></name>
<name><surname>Pop</surname><given-names>L.</given-names></name>
<name><surname>Micl&#x00103;u&#x0015f;</surname><given-names>M.</given-names></name>
<name><surname>H&#x001ce;dade</surname><given-names>N.D.</given-names></name>
<name><surname>Terec</surname><given-names>A.</given-names></name>
<name><surname>Bende</surname><given-names>A.</given-names></name>
<name><surname>Socaci</surname><given-names>C.</given-names></name>
<name><surname>Barboiu</surname><given-names>M.</given-names></name>
<name><surname>Grosu</surname><given-names>I.</given-names></name>
</person-group><article-title>Halogen Bonds (N---I) at Work: Supramolecular Catemeric Architectures of 2,7-Dipyridylfluorene with ortho-, meta-, or para-Diiodotetrafluorobenzene Isomers</article-title><source>Cryst. Growth Des.</source><year>2020</year><volume>20</volume><fpage>3429</fpage><lpage>3441</lpage><pub-id pub-id-type="doi">10.1021/acs.cgd.0c00205</pub-id></element-citation></ref><ref id="B19-pharmaceutics-17-00152"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Micl&#x00103;u&#x0015f;</surname><given-names>M.O.</given-names></name>
<name><surname>Kacso</surname><given-names>I.E.</given-names></name>
<name><surname>Martin</surname><given-names>F.A.</given-names></name>
<name><surname>David</surname><given-names>L.</given-names></name>
<name><surname>Pop</surname><given-names>M.M.</given-names></name>
<name><surname>Filip</surname><given-names>C.</given-names></name>
<name><surname>Filip</surname><given-names>X.</given-names></name>
</person-group><article-title>Crystal Structure and Desolvation Behaviour of the Tadalafil Monosolvates with Acetone and Methyl Ethyl Ketone</article-title><source>J. Pharm. Sci.</source><year>2015</year><volume>104</volume><fpage>3782</fpage><lpage>3788</lpage><pub-id pub-id-type="doi">10.1002/jps.24597</pub-id><pub-id pub-id-type="pmid">26211652</pub-id>
</element-citation></ref><ref id="B20-pharmaceutics-17-00152"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>M.</given-names></name>
<name><surname>Barua</surname><given-names>H.</given-names></name>
<name><surname>Jyothi</surname><given-names>V.G.S.</given-names></name>
<name><surname>Dhondale</surname><given-names>M.R.</given-names></name>
<name><surname>Nambiar</surname><given-names>A.G.</given-names></name>
<name><surname>Agrawal</surname><given-names>A.K.</given-names></name>
<name><surname>Kumar</surname><given-names>P.</given-names></name>
<name><surname>Shastri</surname><given-names>N.R.</given-names></name>
<name><surname>Kumar</surname><given-names>D.</given-names></name>
</person-group><article-title>Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems</article-title><source>Pharmaceutic</source><year>2023</year><volume>15</volume><elocation-id>1161</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15041161</pub-id></element-citation></ref><ref id="B21-pharmaceutics-17-00152"><label>21.</label><element-citation publication-type="book"><source>CrysAlis PRO</source><publisher-name>Rigaku Oxford Diffraction</publisher-name><publisher-loc>Yarnton, UK</publisher-loc><year>2015</year></element-citation></ref><ref id="B22-pharmaceutics-17-00152"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheldrick</surname><given-names>G.M.</given-names></name>
</person-group><article-title>A short history of SHELX</article-title><source>Acta Cryst.</source><year>2008</year><volume>64</volume><fpage>112</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1107/S0108767307043930</pub-id></element-citation></ref><ref id="B23-pharmaceutics-17-00152"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheldrick</surname><given-names>G.M.</given-names></name>
</person-group><article-title>SHELXT&#x02014;Integrated space-group and crystal-structure determination</article-title><source>Acta Cryst.</source><year>2015</year><volume>71</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1107/S2053273314026370</pub-id><pub-id pub-id-type="pmid">25537383</pub-id>
</element-citation></ref><ref id="B24-pharmaceutics-17-00152"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sheldrick</surname><given-names>G.M.</given-names></name>
</person-group><article-title>Crystal structure refinement with SHELXL</article-title><source>Acta Cryst.</source><year>2015</year><volume>71</volume><fpage>3</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1107/S2053229614024218</pub-id></element-citation></ref><ref id="B25-pharmaceutics-17-00152"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dolomanov</surname><given-names>O.V.</given-names></name>
<name><surname>Bourhis</surname><given-names>L.J.</given-names></name>
<name><surname>Gildea</surname><given-names>R.J.</given-names></name>
<name><surname>Howard</surname><given-names>J.A.K.</given-names></name>
<name><surname>Puschmann</surname><given-names>H.</given-names></name>
</person-group><article-title>OLEX2: A complete structure solution, refinement and analysis program</article-title><source>J. Appl. Cryst.</source><year>2009</year><volume>42</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1107/S0021889808042726</pub-id></element-citation></ref><ref id="B26-pharmaceutics-17-00152"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Spackman</surname><given-names>P.R.</given-names></name>
<name><surname>Turner</surname><given-names>M.J.</given-names></name>
<name><surname>McKinnon</surname><given-names>J.J.</given-names></name>
<name><surname>Wolff</surname><given-names>S.K.</given-names></name>
<name><surname>Grimwood</surname><given-names>D.J.</given-names></name>
<name><surname>Jayatilaka</surname><given-names>D.</given-names></name>
<name><surname>Spackman</surname><given-names>M.A.</given-names></name>
</person-group><article-title>CrystalExplorer: A program for Hirshfeld surface analysis, visualization and quantitative analysis of molecular crystals</article-title><source>J. Appl. Crystallogr.</source><year>2021</year><volume>54</volume><fpage>1006</fpage><lpage>1011</lpage><pub-id pub-id-type="doi">10.1107/S1600576721002910</pub-id><pub-id pub-id-type="pmid">34188619</pub-id>
</element-citation></ref><ref id="B27-pharmaceutics-17-00152"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mackenzie</surname><given-names>C.F.</given-names></name>
<name><surname>Spackman</surname><given-names>P.R.</given-names></name>
<name><surname>Jayatilaka</surname><given-names>D.</given-names></name>
<name><surname>Spackman</surname><given-names>M.A.</given-names></name>
</person-group><article-title>CrystalExplorer model energies and energy frameworks: Extension to metal coordination compounds, organic salts, solvates and open-shell systems</article-title><source>IUCrJ</source><year>2017</year><volume>4</volume><fpage>575</fpage><lpage>587</lpage><pub-id pub-id-type="doi">10.1107/S205225251700848X</pub-id><pub-id pub-id-type="pmid">28932404</pub-id>
</element-citation></ref><ref id="B28-pharmaceutics-17-00152"><label>28.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Allen</surname><given-names>F.H.</given-names></name>
<name><surname>Watson</surname><given-names>D.G.</given-names></name>
<name><surname>Brammer</surname><given-names>L.</given-names></name>
<name><surname>Orpen</surname><given-names>A.G.</given-names></name>
<name><surname>Taylor</surname><given-names>R.</given-names></name>
</person-group><source>International Tables for Crystallography</source><edition>3rd ed.</edition><person-group person-group-type="editor">
<name><surname>Prince</surname><given-names>E.</given-names></name>
</person-group><publisher-name>Springer</publisher-name><publisher-loc>Berlin/Heidelberg, Germany</publisher-loc><year>2004</year><fpage>790</fpage><lpage>811</lpage></element-citation></ref><ref id="B29-pharmaceutics-17-00152"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Macrae</surname><given-names>C.F.</given-names></name>
<name><surname>Sovago</surname><given-names>I.</given-names></name>
<name><surname>Cottrell</surname><given-names>S.J.</given-names></name>
<name><surname>Galek</surname><given-names>P.T.A.</given-names></name>
<name><surname>McCabe</surname><given-names>P.</given-names></name>
<name><surname>Pidcock</surname><given-names>E.</given-names></name>
<name><surname>Platings</surname><given-names>M.</given-names></name>
<name><surname>Shields</surname><given-names>G.P.</given-names></name>
<name><surname>Stevens</surname><given-names>J.S.</given-names></name>
<name><surname>Towler</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Mercury 4.0: From visualization to analysis, design and prediction</article-title><source>J. Appl. Crystallogr.</source><year>2020</year><volume>53</volume><fpage>226</fpage><lpage>235</lpage><pub-id pub-id-type="doi">10.1107/S1600576719014092</pub-id><pub-id pub-id-type="pmid">32047413</pub-id>
</element-citation></ref><ref id="B30-pharmaceutics-17-00152"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>Z.</given-names></name>
<name><surname>Yao</surname><given-names>G.</given-names></name>
<name><surname>Xie</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Zhu</surname><given-names>W.</given-names></name>
</person-group><article-title>Pharmaceutical Properties of the Phloretin-4,4&#x02032;-Bipyridine Cocrystal: Structure Analysis, Drug Release Profile, and Antioxidant Activity Research</article-title><source>ACS Omega</source><year>2024</year><volume>9</volume><fpage>31477</fpage><lpage>31487</lpage><pub-id pub-id-type="doi">10.1021/acsomega.4c01136</pub-id><pub-id pub-id-type="pmid">39072064</pub-id>
</element-citation></ref><ref id="B31-pharmaceutics-17-00152"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>L.-X.</given-names></name>
<name><surname>Su</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.-N.</given-names></name>
<name><surname>Yin</surname><given-names>H.-M.</given-names></name>
<name><surname>Zhang</surname><given-names>Q.</given-names></name>
<name><surname>Feng</surname><given-names>T.-R.</given-names></name>
<name><surname>Guo</surname><given-names>Y.-X.</given-names></name>
<name><surname>Zou</surname><given-names>D.-Y.</given-names></name>
<name><surname>Liu</surname><given-names>Y.-L.</given-names></name>
</person-group><article-title>A Cocrystal of Baicalein and 4,4&#x02032;-Bipyridine with Zipper-Type Architecture</article-title><source>J. Chem. Crystallogr.</source><year>2021</year><volume>51</volume><fpage>363</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1007/s10870-020-00853-2</pub-id></element-citation></ref><ref id="B32-pharmaceutics-17-00152"><label>32.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Socrates</surname><given-names>G.</given-names></name>
</person-group><source>Infrared and Raman Characteristic Group Frequencies,Tables and Charts</source><edition>3rd ed.</edition><publisher-name>John Wiley &#x00026; Sons Ltd.</publisher-name><publisher-loc>Chichester, UK</publisher-loc><year>2004</year></element-citation></ref></ref-list><sec sec-type="display-objects"><title>Figures, Scheme and Tables</title><fig position="float" id="pharmaceutics-17-00152-sch001"><object-id pub-id-type="pii">pharmaceutics-17-00152-sch001_Scheme 1</object-id><label>Scheme 1</label><caption><p>Cardarine solid forms and derivatives.</p></caption><graphic xlink:href="pharmaceutics-17-00152-sch001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f001"><label>Figure 1</label><caption><p>The molecular structure of GW-6 showing the atomic numbering and 50% probability displacement ellipsoids (<bold>a</bold>); a portion of the crystal packing viewed along the b axis and showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g001" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f002"><label>Figure 2</label><caption><p>The molecular structure of GW-Bipy 2:1 cocrystal showing the atomic numbering and 50% probability displacement ellipsoids. The bipyridine molecule is situated on inversion center (<bold>a</bold>); a portion of the crystal packing viewed along the a-axis and showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g002" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f003"><label>Figure 3</label><caption><p>The molecular structure of GW-DMF showing the atomic numbering and 50% probability displacement ellipsoids (<bold>a</bold>); a portion of the crystal packing viewed along the a-axis and showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g003" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f004"><label>Figure 4</label><caption><p>The molecular structure of GW-MeOH showing the atomic numbering and 50% probability displacement ellipsoids (<bold>a</bold>); a portion of the crystal packing viewed along the a-axis and showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g004a" position="float"/><graphic xlink:href="pharmaceutics-17-00152-g004b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f005"><label>Figure 5</label><caption><p>The molecular structure of GW-SO shows the atomic numbering and 50% probability displacement ellipsoids (<bold>a</bold>); a portion of the crystal packing showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g005a" position="float"/><graphic xlink:href="pharmaceutics-17-00152-g005b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f006"><label>Figure 6</label><caption><p>The molecular structure of GW-SO<sub>2</sub> showing the atomic numbering and 50% probability displacement ellipsoids (<bold>a</bold>); a portion of the crystal packing viewed along the b-axis and showing intermolecular interactions as thin blue lines (<bold>b</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g006a" position="float"/><graphic xlink:href="pharmaceutics-17-00152-g006b" position="float"/></fig><fig position="float" id="pharmaceutics-17-00152-f007"><label>Figure 7</label><caption><p>DTA and TGA curves of the analyzed new crystalline forms: the GW-polymorph (<bold>a</bold>); the GW-MeOH solvate (<bold>b</bold>); the GW-DMF solvate (<bold>c</bold>); the 2:1 GW-Bipy cocrystal (<bold>d</bold>); the 4,4&#x02032;-bipyridine conformer (<bold>e</bold>); and TGA curves of new crystalline forms compared with the GW cardarine start compound (<bold>f</bold>).</p></caption><graphic xlink:href="pharmaceutics-17-00152-g007a" position="float"/><graphic xlink:href="pharmaceutics-17-00152-g007b" position="float"/><graphic xlink:href="pharmaceutics-17-00152-g007c" position="float"/></fig><table-wrap position="float" id="pharmaceutics-17-00152-t001"><object-id pub-id-type="pii">pharmaceutics-17-00152-t001_Table 1</object-id><label>Table 1</label><caption><p>Detailed single crystal X-ray diffraction data of the cardarine-based crystalline forms and derivatives.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
<bold>Identification code</bold>
</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-6</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-Bipy</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-MeOH</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-DMF</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-SO</td><td align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">GW-SO<sub>2</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Empirical formula</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>S<sub>2</sub>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>2</sub>O<sub>3</sub>S<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>22</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>4</sub>S<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>24</sub>H<sub>25</sub>F<sub>3</sub>N<sub>2</sub>O<sub>4</sub>S<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"> C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>4</sub>S<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C<sub>21</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>5</sub>S<sub>2</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Formula weight</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">453.48 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">531.57</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">485.52</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">526.58</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">938.97</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">485.48</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Temperature/K</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293(2) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">293(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">250(60)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crystal system</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">monoclinic </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">triclinic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">monoclinic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">triclinic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">triclinic</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">monoclinic</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Space group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P2<sub>1</sub>/n </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P2<sub>1</sub>/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P2<sub>1</sub>/n</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">a/&#x000c5;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8413(6) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8765(5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6702(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.6428(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.7781(9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6735(4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">b/&#x000c5;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.7961(15) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.418(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10.9176(4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11.6468(3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12.8498(14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27.738(2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">c/&#x000c5;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.778(6) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.734(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.4184(18)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.5294(4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15.1481(19)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16.3811(14)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b1;/&#x000b0;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.787(10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.443(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108.143(10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;/&#x000b0;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">92.100(11) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93.949(10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.048(4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96.521(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">101.939(9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">91.101(7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b3;/&#x000b0;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95.890(10)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98.027(2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90.002(8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Volume/&#x000c5;<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2129.9(5) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1248.3(3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2264.40(16)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1257.02(6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2126.4(4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2123.2(3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Z</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003c1;calc g/cm<sup>3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.414 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.414</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.424</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.391</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.467</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.519</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003bc;/mm<sup>&#x02212;1</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.708 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.410</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.617</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.414</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.305</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.831</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F(000)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">936.0 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">550.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1008.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">548.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">968.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Radiation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cu K&#x003b1; (&#x003bb; = 1.54184) </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CuK&#x003b1; (&#x003bb; = 1.54184)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CuK&#x003b1; (&#x003bb; = 1.54184)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CuK&#x003b1; (&#x003bb; = 1.54184)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MoK&#x003b1; (&#x003bb; = 0.71073)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CuK&#x003b1; (&#x003bb; = 1.54184)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x00398; range/&#x000b0;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.506 to 143.838 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.748 to 142.094</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.964 to 141.562</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7.672 to 141.262</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.698 to 58.392</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.268 to 155.142</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Index ranges</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;3 &#x02264; h &#x02264; 5, &#x02212;13 &#x02264; k &#x02264; 12, &#x02212;49 &#x02264; l &#x02264; 49 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5 &#x02264; h &#x02264; 4, &#x02212;18 &#x02264; k &#x02264; 18, &#x02212;20 &#x02264; l &#x02264; 18</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5 &#x02264; h &#x02264; 5, &#x02212;13 &#x02264; k &#x02264; 12, &#x02212;36 &#x02264; l &#x02264; 54</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;7 &#x02264; h &#x02264; 7, &#x02212;14 &#x02264; k &#x02264; 14, &#x02212;20 &#x02264; l &#x02264; 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;15 &#x02264; h &#x02264; 15, &#x02212;16 &#x02264; k &#x02264; 16, 0 &#x02264; l &#x02264; 20</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;5 &#x02264; h &#x02264; 4, &#x02212;33 &#x02264; k &#x02264; 33, &#x02212;19 &#x02264; l &#x02264; 19</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reflections collected</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12,724 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8016</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13,932</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24,502</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9745</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29,479</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Independent reflections</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4059 [R<sub>int</sub> = 0.1228, R<sub>sigma</sub> = 0.1257] </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4663 [R<sub>int</sub> = 0.0324, R<sub>sigma</sub> = 0.0496]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4318 [R<sub>int</sub> = 0.0498, R<sub>sigma</sub> = 0.0420]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4746 [R<sub>int</sub> = 0.0327, R<sub>sigma</sub> = 0.0174]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9745 [R<sub>int</sub> = 0.0942, R<sub>sigma</sub> = 0.1406]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4062 [R<sub>int</sub> = 0.1141, R<sub>sigma</sub> = 0.0818]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Data/restraints/parameters</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4059/0/275 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4663/1/331</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4318/0/294</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4746/0/349</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9745/0/566</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4062/0/292</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Goodness-of-fit on F2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.025</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.027</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.095</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.047</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.044</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.068</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Final R indexes [I &#x02265; 2&#x003c3; (I)]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.1407, wR<sub>2</sub> = 0.3113 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0540, wR<sub>2</sub> = 0.1330</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0646, wR<sub>2</sub> = 0.1957</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0442, wR<sub>2</sub> = 0.1568</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.1173, wR<sub>2</sub> = 0.2813</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0774, wR<sub>2</sub> = 0.2032</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Final R indexes [all data]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.2255, wR<sub>2</sub> = 0.3653 </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0756, wR<sub>2</sub> = 0.1596</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0751, wR<sub>2</sub> = 0.2059</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.0468, wR<sub>2</sub> = 0.1618</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.2136, wR<sub>2</sub> = 0.3545</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">R<sub>1</sub> = 0.1128, wR<sub>2</sub> = 0.2332</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Largest diff. peak/hole/e &#x000c5;<sup>&#x02212;3</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.46/&#x02212;0.56</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.23/&#x02212;0.32</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.27/&#x02212;0.39</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.18/&#x02212;0.38</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.16/&#x02212;0.41</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.43/&#x02212;0.67</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00152-t002"><object-id pub-id-type="pii">pharmaceutics-17-00152-t002_Table 2</object-id><label>Table 2</label><caption><p>Melting points of the solid forms compared with the previous reported polymorphs GW1 to GW-5.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystal</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Melting Point (&#x000b0;C)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-1</td><td align="center" valign="middle" rowspan="1" colspan="1">142</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-2</td><td align="center" valign="middle" rowspan="1" colspan="1">137</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-3</td><td align="center" valign="middle" rowspan="1" colspan="1">139</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-4</td><td align="center" valign="middle" rowspan="1" colspan="1">131</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-5</td><td align="center" valign="middle" rowspan="1" colspan="1">139 and 145</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-6</td><td align="center" valign="middle" rowspan="1" colspan="1">130 and 134</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-MeOH</td><td align="center" valign="middle" rowspan="1" colspan="1">121 and 135</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">GW-DMF</td><td align="center" valign="middle" rowspan="1" colspan="1">133 and 144</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-Bipy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">123</td></tr></tbody></table></table-wrap><table-wrap position="float" id="pharmaceutics-17-00152-t003"><object-id pub-id-type="pii">pharmaceutics-17-00152-t003_Table 3</object-id><label>Table 3</label><caption><p>Crystal lattice energies of the six cardarine-based crystalline forms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Crystal</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>ele</sub>(kJ/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>pol</sub> (kJ/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>disp</sub> (kJ/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>rep</sub> (kJ/mol)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">E<sub>latt</sub> (kJ/mol)</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;77.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;18.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;188.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">51.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;233.3</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-Bipy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;37.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;139.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;151.4</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-MeOH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;47.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;10.1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;141.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;152.7</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-DMF</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;50.9</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;12.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;146.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;169.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-SO</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;107.6</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;20.3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;180.5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">97.8</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;210.6</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GW-SO<sub>2</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;107.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;14.2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;204.7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66.4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;260.2</td></tr></tbody></table></table-wrap></sec></back></article>